Dren Bio, a privately held, clinical-stage biotechnology company based in San Carlos, California, announced on October 29, 2026, that it has closed an oversubscribed $350 million private financing. The round was co-led by Juvia Group and Lightspeed Venture Partners.
New investors in the round included Mirae Asset Capital Life Science, General Catalyst, Cormorant Asset Management, and OrbiMed. Participating existing investors included 8VC, SR One, Taiho Ventures, Mission BioCapital, HBM Healthcare Investments, BVF Partners, Aisling Capital, and ArrowMark Partners. In connection with the financing, Juvia Group co-founder and managing director Sujal Shah and Lightspeed partner Shelley Chu joined Dren Bio's board of directors.
The financing is one of biotech's largest private rounds of the year, and a sharp step up from Dren Bio's previous fundraise, a $65 million Series B in 2022. The company did not label the new round with a series designation.
What Dibotatug Is
Dren Bio develops first-in-class antibody therapeutics for cancer, autoimmune, and other serious diseases. Its lead therapy, dibotatug (also known as DR-01), is an investigational, fully human monoclonal antibody that targets a protein called CD94.
The concept is selective depletion. In certain blood cancers and autoimmune diseases, a population of cytotoxic immune cells becomes pathogenic — it attacks the body or drives disease. Dibotatug is designed to selectively remove those disease-causing cells while preserving the broader immune system. That selectivity is the key differentiator: older approaches to depleting immune cells often suppress immunity broadly, leaving patients vulnerable to infection.
Dibotatug is being developed for hematologic malignancies, nonmalignant hematologic disorders, and autoimmune diseases. Its most advanced studies involve cytotoxic T-cell lymphoma (CTL) and large granular lymphocytic leukemia (LGLL), two rare blood cancers for which the company says there are currently no approved therapies.
The Clinical Picture So Far
More than 300 patients have received dibotatug in Phase 1/2 studies in relapsed or refractory CTL and LGLL, according to the company. Dren Bio said the studies showed overall and complete responses in these patients, but the financing announcement provided no numerical response rates, so the strength of the signal cannot be independently assessed from the announcement alone.
A primary readout from the CTL and LGLL trial is slated for December 2026, according to trial records cited in coverage. Dren Bio lists the hematologic malignancy program as being in registrational development, meaning the company intends the current studies to support a regulatory submission. The company also plans to expand dibotatug into aplastic anemia, other bone marrow failure syndromes, and autoimmune indications.
The financing proceeds will support continued late-stage clinical development, regulatory submission, and the planned commercial launch of dibotatug, as well as acceleration of the company's broader pipeline.
The Broader Pipeline and Platform
Beyond dibotatug, Dren Bio is advancing programs based on its Targeted Myeloid Engager and Phagocytosis Platform, a technology that uses antibodies to engage immune cells that remove disease-causing targets. The platform has already produced a commercial validation: its lead program, DR-0201, now known as SAR448501, was acquired by Sanofi in May 2025 for $600 million upfront. A second candidate, DR-0202, is being evaluated for solid tumors. Dren Bio has also drawn investment and partnerships from major pharmaceutical companies including Novartis and Pfizer.
This history matters for understanding the $350 million round. Investors are not only funding a single drug; they are funding a platform that has already generated a large pharma transaction, plus a late-stage lead asset approaching regulatory submission.
What It Means for Founders and Investors
For biotech founders, Dren Bio's round illustrates how late-stage capital is raised in 2026. The ingredients are: a differentiated mechanism (selective depletion rather than broad immunosuppression), a lead asset in registrational development with a near-term readout, a platform with a prior pharma deal, and a syndicate that mixes new crossover investors with existing backers. The oversubscribed label and the breadth of the syndicate signal that investors were competing for allocation, not being courted.
For investors, the risk is equally clear. Dibotatug remains investigational and has not received regulatory approval. Further clinical studies and regulatory reviews will be required to establish its safety and effectiveness, and the December readout will be the first hard test of the investment thesis. The $350 million gives Dren Bio the capital to reach submission and prepare a commercial launch, but in biotech, capital buys the chance to prove a drug works — it does not prove it.
Angeled.com connects founders with investors.
BioSpace, "Dren Bio lands $350M to push rare blood cancer therapy toward market,"
Source: pulse2.com
Pulse2, "Dren Bio Raises $350 Million To Advance Dibotatug And Broader Therapeutics Pipeline,"
Source: americanpharmaceuticalreview.com
American Pharmaceutical Review, "Dren Bio Raises $350 Million for Blood Cancer Drug Development,"
Source: pharmaceutical-technology.com
Pharmaceutical Technology, "Dren Bio raises $350m for dibotatug clinical development,"
Read Next
General Translation Raises $27 Million Series A Led by a16z to Build Agent-First Localization Infrastructure
LangChain Raises $300 Million Led by CapitalG at a $3 Billion Valuation to Build the Agent Stack
Mount Thor Raises $45 Million to Run Cloud Fleets of Macs for AI Agents
OpenAI Reportedly Raises $15 Billion at a $1.25 Trillion Valuation
Q-CTRL Raises $290 Million Series C Led by Salesforce Ventures, Reaching Unicorn Status
SE3 Raises $30 Million Series A Led by Accel



